Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19)

JAMA Netw Open. 2020 Jul 1;3(7):e2016485. doi: 10.1001/jamanetworkopen.2020.16485.

Abstract

This case series examines whether interleukin 7 (IL-7) is associated with restored host protective immunity in patients with severe coronavirus disease 2019 (COVID-19) and immunosuppression.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Betacoronavirus / immunology*
  • COVID-19
  • Case-Control Studies
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Cytokines / immunology
  • Female
  • Humans
  • Immunotherapy / methods*
  • Interleukin-7 / administration & dosage
  • Interleukin-7 / therapeutic use*
  • Lymphocyte Count / methods
  • Lymphopenia / etiology
  • Lymphopenia / mortality
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • Randomized Controlled Trials as Topic
  • SARS-CoV-2

Substances

  • Cytokines
  • IL7 protein, human
  • Interleukin-7